Keros Therapeutics and Takeda Finalize Global License Agreement for Elritercept

Keros Therapeutics, a clinical-stage biopharmaceutical company, has announced the effectiveness of its global license agreement with Takeda to advance the development and commercialization of elritercept, a promising therapeutic candidate for treating hematologic disorders. This agreement, initially disclosed on December 3, 2024, became effective following the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

Under the terms of the agreement, Keros will receive a $200 million upfront payment and is eligible for additional development, approval, and commercial milestone payments that could exceed $1.1 billion. Keros will also be entitled to tiered royalties on net sales of elritercept. Takeda will assume responsibility for the global development, manufacturing, and commercialization of elritercept, aiming to bring this potential treatment to patients with hematologic disorders worldwide.